Skip to content
Menu

Personalis, Inc. PSNL

Full chart Compare
Set alert

Price alert · PSNL

All alert types
14.27 USD -0.45 (-3.06%)

Regular-session close

14.27 0.00 0.00%

After hours · Nov 20, 4:26 PM ET

14.23 Day range 14.67
4.96 52-week range 18.89
YTD
+79.27%
1 year
+72.34%

5D -1.00 (-6.31%)

14.501515.5016FriMonTueWedThu14.86
Market cap
1.55B
Revenue (ttm)
80.77M
Profit margin
-147.74%
EPS (ttm)
-1.16
Shares out
108.40M
Forward P/E
-14.53
YTD return
+79.27%
1-year return
+72.34%
50-day average
15.93
200-day average
11.69
Volume
3.34M
Avg volume
2.56M
Open
14.55
Previous close
14.72
Day's range
14.23 – 14.67
52-week range
4.96 – 18.89
Beta
2.36
Analysts
Hold
Price target
15.17 (+6.3%)
Earnings date
Feb 25, 2027

Key statistics

Enterprise value
1.44B
Price / sales
19.15
Price / book
7.27
Revenue growth
76.60%
Free cash flow
-59.35M
Total cash
190.60M
Total debt
37.20M
Return on equity
-62.14%
Short % of float
9.64%

Fundamental scorecard

4 of 25 checks passed on PSNL’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
PSNL Revenue — quarterly 25.60M
PSNL Net income — quarterly -33.80M
PSNL EPS — quarterly -0.32

Earnings

PSNL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 25, 2027Dec 30, 2026-0.2365———
Nov 4, 2026Sep 30, 2026-0.26333-0.32-0.06-21.52%
Aug 4, 2026Jun 30, 2026-0.26333-0.30-0.04-13.93%
May 7, 2026Mar 31, 2026-0.23-0.29-0.06-26.09%
Feb 26, 2026Dec 31, 2025-0.31-0.26+0.05+16.13%
Nov 4, 2025Sep 30, 2025-0.28-0.24+0.04+14.29%

Upgrades / downgrades

PSNL analyst upgrades and downgrades
DateFirmActionFromTo
Oct 6, 2026BTIGdownBuyNeutral
Jul 20, 2026Lake StreetdownBuyHold
Jul 20, 2026BTIGmainBuyBuy
Jul 20, 2026NeedhamdownBuyHold
Jul 17, 2026NeedhammainBuyBuy
Jul 9, 2026Morgan StanleymainEqual-WeightEqual-Weight

About Personalis, Inc.

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and cancer patients. The company has strategic collaboration with Tempus AI, Inc. to bring testing to colorectal cancer patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States

News

Your note

Sign in to keep a note on PSNL — it syncs with the Stock Master app.

Insider holders

PSNL insider holders
InsiderRelationLatest transactionDateShares held
BLOOM OLIVIA KYUSUKDirectorStock Award(Grant)May 11, 202627,265
BOWMAN ARTHUR BLAINEDirectorStock Award(Grant)May 11, 202619,756
CHEN RICHARDPresidentSaleSep 17, 2026169,882
EASTHAM KARINDirectorStock Award(Grant)May 11, 202619,756
HALL CHRISTOPHER M.Chief Executive OfficerSaleNov 2, 2026199,415
MOORE STEPHEN MICHAELOfficerSaleSep 17, 202690,257

Institution ownership

PSNL institution ownership
Holder% heldSharesValueReported
Merck & Co., Inc.12.96%14,044,943200.42MSep 29, 2026
ARK Investment Management, LLC6.57%7,119,390101.59MSep 29, 2026
Blackrock Inc.6.40%6,934,01798.95MSep 29, 2026
Lightspeed Management Company, L.L.C. 5.63%6,101,85087.07MSep 29, 2026
Balyasny Asset Management LP4.57%4,958,94270.76MSep 29, 2026
Aberdeen Group plc3.21%3,480,94949.67MSep 29, 2026

Fund ownership

PSNL fund ownership
Holder% heldSharesValueReported
abrdn Healthcare Investors2.03%2,204,51631.46MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund1.98%2,142,39530.57MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF1.73%1,878,90326.81MSep 29, 2026
abrdn Life Sciences Investors1.42%1,542,77422.02MJun 29, 2026
Columbia Acorn Trust-Columbia Acorn Fund1.18%1,277,62818.23MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF1.07%1,160,16316.56MOct 30, 2026